Psychotic- vs. Psychedelic-Induced Hallucinations: A Closer Look

Are there more differences than similarities?


The perception of the senses is partially driven by the past experiences, the thoughts at the moment and the expectations for the future, in what is called top-down brain processing.1 This means that the minds’ background influences how senses are perceived. Thereupon, the sight can play tricks on the brain and vice-versa. For example, it is not uncommon to see shapes that look like objects and things that are not really there. 

Interestingly, these experiences fit reasonably into the definition of hallucinations, which is the perception occurring inside the brain in the absence of the corresponding external stimulus.2 It is true that hallucinations are frequently correlated to psychotic disorders, which makes sense since it is one of the five remarkable symptoms of diagnostic criteria for them.1 However, it is not an exclusive feature of brain malfunction and can be experienced by healthy subjects.3

Physicians have proposed in the past that the altered state of consciousness induced by psychedelics could share neural mechanisms and clinical features with psychosis, constituting – therefore – a reliable “model of psychosis.”4 This theory was fairly well accepted by mainstream culture and even among specialists for some decades. LSD, upon its discovery, was given to people and self-administered by doctors in order to mimic psychosis and better understand it. However, a deeper look into the neurobiological and phenomenological perspectives about hallucinations reveals that they are more nuanced than previously believed regarding the related mechanisms underlying these two experiences.

The Two Experiences Compared Using Different Approaches  

The first thing to pinpoint is that it is not completely clear whether synesthesia and synesthesia-like experiences qualify or not as hallucinations. That would be a distinctive feature since they occur very often under serotonergic psychedelics but are quite uncommon in psychotic episodes.5,6  Synesthesia is characterized by the blending of the different senses producing the sensation of a different modality, such as hearing shapes and tasting colors.

In terms of the consensual definition of hallucinations, the most common modality in schizophrenia is by far the auditive one, whereas psychedelic-induced hallucinations occur mostly for visual processing.6–9 When present, visual hallucinations in schizophrenia are highly detailed and concrete, typically reproducing faces and events from real life.10 On the other hand, psychedelic-induced visuals are often elementary (fractals, spirals, cobwebs, and geometric patterns), although sometimes more complex hallucinations can occur under higher and heroic doses.9 However, people under psychedelics usually preserve the acknowledgment about the etiology of hallucinations and can distinguish between drug effects and reality whilst schizophrenic patients lose their self-monitoring of reality.11,12

The molecular mechanisms underlying schizophrenia at the neurotransmitter level are not completely understood by pharmacologists. But, they are known to be mostly linked to dopamine signaling, while psychedelics are use mostly serotonin receptors.13 Still, some psychedelic drugs mimic certain aspects of schizophrenia, especially paranoia. 

A man sits holding his temples. worried.

StunningArt / Shutterstock

A couple of antipsychotics were discovered empirically in the past by their assumed ability to neutralize LSD effects, supporting psychedelics as a model for psychosis.14 However, LSD also interacts with dopamine receptors, and serotonergic-only high-affinity antagonists show little or no efficacy as antipsychotics. Therefore, if the mechanisms were exactly the same, some psychedelics that act only at serotonin receptors (such as phenethylamines) would not induce hallucinogenic experiences.15,16 Moreover, a compound named ketanserin (serotonin receptor blocker) effectively abolishes the psychedelic subjective experience and has little effect on dopamine receptors.17

When it comes to brain imaging studies, the differences and similarities between these two phenomena become foggy. The onset of hallucination in schizophrenic patients is correlated with hyperactivity within associative cortices related to the hallucinatory modality (i.e., auditive, visual, etc) rather than primary sensory cortices. LSD and psilocybin seem to induce the opposite –  overactivation of primary cortices and reduced association.18,19  However, both psychotic- and psychedelic-induced hallucinations are associated with reduced stability of functional brain networks, such as the disintegration of resting-state networks. Recently, a comprehensive speech analysis pushed away the kinship between psychedelic-induced and schizophrenic behavior using machine learning algorithms.20 Computational modelling now can help to make inferences about the shared mechanisms and clarify whether or not psychedelics trigger psychotic-like hallucinations.

Concluding Remarks

In summary, there are probably more differences than similarities underlying psychotic and psychedelic-induced hallucination experiences. It cannot be overlooked that the social stigma and political constraints – that marked the whole history of psychedelics in modern western culture – can shape the general thinking of these drugs as harmful for brain health and devoid of therapeutic value. 

It is important to mention that when analyzing answers from more than 135,000 respondents of the US National Survey on Drug Use and Health (NSDUH), individuals who declared having used a “classic” psychedelic at least once were not at increased risk of developing mental health issues, including schizophrenia, psychotic episodes, and suicide attempts.21 

Psychedelics are believed to be useful tools to treat neuropsychiatric conditions and visual hallucinations are part of the insightful experiences that some argue being necessary for therapeutic effects.22 Still, the promising therapeutic potential and possible differences between psychosis- and psychedelic-induced hallucinations do not refute the strong contraindication for patients with psychotic disorders or a predisposition to developing them.23

José is a biomedical scientist, specialist in Neurorehabilitation, master in Cell Biology, and Assistant Professor of Tissue Biology based in Brazil. He is currently pursuing his PhD in Cellular Biology, investigating the effects of psychedelics on brain organoids at the Federal University of Rio de Janeiro (UFRJ).


Notify of

Newest Most Voted
Inline Feedbacks
View all comments
2 years ago

Typo: “while psychedelics are use mostly serotonin receptors”

Would like to see more research into schizophrenia. I’ve wondered if the schizophrenic state is similar to the psychedelic state, in that the former may be experiencing their unconscious thoughts in the same what that psychedelics allow you to pass through the barrier or “veil” that separates conscious thought from unconscious thought. i.e. They do not have a stable barrier.

Elizabeth Elhamri
2 years ago

I took LSD a few times in my twenties with no ill effects…just watching everything take on amazing colours and finding myself unable to speak coherently for a while. Many years later I had a psychosis after build up of emotional and work stress aggravated by feeling unable to admit or disclose to anyone what I was going through. I became paranoid and felt the world had reversed and imploded on me but I eventually recovered and I’ve been fine since. I kept trying to escape and then realised that I was still me, the grass was still green, the… Read more »

Elizabeth Elhamri
2 years ago

Nuts. Just posted. Now it’s gone. Well I’m not going to repeat myself but I’d like to add that as lucid dreams come readily to me without taking back up drugs, and have done since I was a young child, I personally will never take psychedelic drugs x even if I did a few times in my early twenties

  1. Katsuki F, Constantinidis C. Bottom-up and top-down attention: Different processes and overlapping neural systems. Neuroscientist. 2014;20(5):509-521. doi:10.1177/1073858413514136
  2. Telles-Correia D, Moreira AL, Gonçalves JS. Hallucinations and related concepts-their conceptual background. Front Psychol. 2015;6. doi:10.3389/fpsyg.2015.00991
  3. Waters F, Fernyhough C. Hallucinations: A systematic review of points of similarity and difference across diagnostic classes. Schizophr Bull. 2017;43(1):32-43. doi:10.1093/schbul/sbw132
  4. Bercel NA, Travis LE, Olinger LB, Dreikurs E, Polos MG. Model Psychoses Induced by LSD-25 in Normals: I. Psychophysiological Investigations, with Special Reference to the Mechanism of the Paranoid Reaction. Arch Neurol Psychiatry. 1956;75(6):588-611. doi:10.1001/archneurpsyc.1956.02330240026003
  5. Waters F, Collerton D, Ffytche DH, et al. Visual hallucinations in the psychosis spectrum and comparative information from neurodegenerative disorders and eye disease. Schizophr Bull. 2014;40(SUPPL. 4). doi:10.1093/schbul/sbu036
  6. Luke DP, Terhune DB. The induction of synaesthesia with chemical agents: a systematic review. Front Psychol. 2013;4. doi:10.3389/fpsyg.2013.00753
  7. Clark ML, Waters F, Vatskalis TM, Jablensky A. On the interconnectedness and prognostic value of visual and auditory hallucinations in first-episode psychosis. Eur Psychiatry. 2017;41:122-128. doi:10.1016/j.eurpsy.2016.10.011
  8. Oorschot M, Lataster T, Thewissen V, et al. Symptomatic remission in psychosis and real-life functioning. Br J Psychiatry. 2012;201(3):215-220. doi:10.1192/bjp.bp.111.104414
  9. Masters R, Houston J. The Varieties of Psychedelic Experience. J Psychedelic Drugs. 1968;1(2):124-132. doi:10.1080/02791072.1968.10524526
  10. Nayani TH, David AS. The auditory hallucination: A phenomenological survey. Psychol Med. 1996;26(1):177-189. doi:10.1017/s003329170003381x
  11. Proust J, Fortier M. Metacognitive Diversity: An Interdisciplinary Approach. Oxford University Press; 2018. doi:10.1093/oso/9780198789710.001.0001
  12. Sanz C, Tagliazucchi E. The experience elicited by hallucinogens presents the highest similarity to dreaming within a large database of psychoactive substance reports. Front Neurosci. 2018;12(JAN). doi:10.3389/fnins.2018.00007
  13. González-Maeso J, Sealfon SC. Psychedelics and schizophrenia. Trends Neurosci. 2009;32(4):225-232. doi:10.1016/j.tins.2008.12.005
  14. Colpaert FC. Discovering risperidone: The LSD model of psychopathology. Nat Rev Drug Discov. 2003;2(4):315-320. doi:10.1038/nrd1062
  15. de Paulis T. M-100907 (Aventis). Curr Opin Investig Drugs. 2001;2(1):123-132. Accessed February 25, 2021.
  16. Geyer MA, Vollenweider FX. Serotonin research: Contributions to understanding psychoses. Trends Pharmacol Sci. 2008;29(9):445-453. doi:10.1016/
  17. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897-3902. doi:10.1097/00001756-199812010-00024
  18. Jardri R, Thomas P, Delmaire C, Delion P, Pins D. The neurodynamic organization of modality-dependent hallucinations. Cereb Cortex. 2013;23(5):1108-1117. doi:10.1093/cercor/bhs082
  19. Lefebvre S, Demeulemeester M, Leroy A, et al. Network dynamics during the different stages of hallucinations in schizophrenia. Hum Brain Mapp. 2016;37(7):2571-2586. doi:10.1002/hbm.23197
  20. Sanz C, Pallavicini C, Carrillo F, et al. The entropic tongue: Disorganization of natural language under LSD. Conscious Cogn. 2021;87:103070. doi:10.1016/j.concog.2020.103070
  21. Johansen PO, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: A population study. J Psychopharmacol. 2015;29(3):270-279. doi:10.1177/0269881114568039
  22. Yaden DB, Griffiths RR. The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol Transl Sci. Published online 2021. doi:10.1021/acsptsci.0c00194
  23. Rucker JJH, Iliff J, Nutt DJ. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. Published online December 25, 2017. doi:10.1016/J.NEUROPHARM.2017.12.040